Media stories about Eiger BioPharmaceuticals (NASDAQ:EIGR) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eiger BioPharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.3092013611626 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

Shares of Eiger BioPharmaceuticals (EIGR) opened at $10.85 on Tuesday. Eiger BioPharmaceuticals has a one year low of $6.10 and a one year high of $13.95. The company has a current ratio of 5.78, a quick ratio of 5.78 and a debt-to-equity ratio of 1.19.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.28) by $0.18. analysts expect that Eiger BioPharmaceuticals will post -5.35 EPS for the current fiscal year.

Several research firms have recently issued reports on EIGR. Oppenheimer Holdings, Inc. set a $34.00 target price on shares of Eiger BioPharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research upgraded shares of Eiger BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Monday, October 16th. Roth Capital began coverage on shares of Eiger BioPharmaceuticals in a research note on Thursday, October 19th. They issued a “buy” rating and a $35.00 target price for the company. Wedbush reiterated a “buy” rating on shares of Eiger BioPharmaceuticals in a research note on Wednesday, October 25th. Finally, ValuEngine upgraded shares of Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Eiger BioPharmaceuticals presently has an average rating of “Buy” and an average target price of $30.43.

COPYRIGHT VIOLATION WARNING: “Eiger BioPharmaceuticals (EIGR) Earns Daily Media Sentiment Score of 0.12” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at

In related news, Director Jeffrey S. Glenn purchased 15,000 shares of Eiger BioPharmaceuticals stock in a transaction that occurred on Friday, September 1st. The stock was bought at an average price of $9.53 per share, for a total transaction of $142,950.00. Following the completion of the transaction, the director now owns 31,355 shares in the company, valued at $298,813.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 28.80% of the stock is currently owned by corporate insiders.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Insider Buying and Selling by Quarter for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with's FREE daily email newsletter.